Piramal Life Sciences Limited, part of the Piramal Group of companies, has received regulatory approval for the initiation of a phase-I study of a new cancer compound, P-1446A-05, in Canada.
P-1446A-05 is an orally active compound being developed for the treatment of advanced cancer. P-1446A-05 is a CDK-4 inhibitor and has higher oral bioavailability. In contrast to most cancer drugs this drug can be given orally increasing patient compliance and reducing hospital costs.
Piramal Life Sciences had submitted the Clinical Trial Application (CTA) for P-1446A-05 to Health Canada, Canada's regulatory authority.
Dr Swati Piramal, director, Piramal Group, said, "Piramal Life Sciences is dedicated to finding new cures in cancer. Committed to the Group's values – knowledge, action and care, it focuses upon nurturing innovation and breakthrough thinking to impact the lives of millions, in dynamic, nimble-footed delivery and in making quality drugs accessible. We are happy and proud that our world-class dossier for P-1446A-05 has been accepted by the Canadian regulatory authorities. Our earlier cancer compound P276 has completed phase-I studies in Canada as well."
Dr Somesh Sharma, managing director, Piramal Life Sciences, stated, "This is our seventh entity to enter the clinic and bears testimony to our efforts to build a diversified and strong pipeline of products to address unmet medical needs."